tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

PHVS Stock Latest News

Pharvaris Raises $201 Million in Successful Offering
Company AnnouncementsPharvaris Raises $201 Million in Successful Offering
18d ago
6K
PHVS
Pharvaris 8.25M share Spot Secondary priced at $20.00
PremiumThe Fly
Pharvaris 8.25M share Spot Secondary priced at $20.00
20d ago
PHVS
Pharvaris announces $150M ordinary shares offering
PremiumThe Fly
Pharvaris announces $150M ordinary shares offering
20d ago
PHVS
Pharvaris’s Accelerated Phase 3 Trial Timeline and Market Potential Boost Buy Rating
PremiumRatings
Pharvaris’s Accelerated Phase 3 Trial Timeline and Market Potential Boost Buy Rating
1M ago
PHVS
Pharvaris’s Promising Outlook: Accelerated Timeline and Market Potential for Deucrictibant in HAE Treatment
PremiumRatings
Pharvaris’s Promising Outlook: Accelerated Timeline and Market Potential for Deucrictibant in HAE Treatment
1M ago
PHVS
Pharvaris Updates RAPIDe-3 Study Timeline for HAE Treatment
PremiumCompany AnnouncementsPharvaris Updates RAPIDe-3 Study Timeline for HAE Treatment
1M ago
6K
PHVS
Pharvaris to report topline Phase 3 results of deucrictibant in Q4
Premium
The Fly
Pharvaris to report topline Phase 3 results of deucrictibant in Q4
1M ago
PHVS
Pharvaris Announces Key Resolutions from Annual General Meeting
Premium
Company Announcements
Pharvaris Announces Key Resolutions from Annual General Meeting
2M ago
6K
PHVS
Pharvaris initiated with a Buy at Guggenheim on HAE potential
PremiumThe Fly
Pharvaris initiated with a Buy at Guggenheim on HAE potential
2M ago
PHVS
Pharvaris initiated with a Buy at Guggenheim
PremiumThe Fly
Pharvaris initiated with a Buy at Guggenheim
2M ago
PHVS
Pharvaris Announces 2025 Annual Shareholders Meeting Amidst Phase 3 Trials
PremiumCompany Announcements
Pharvaris Announces 2025 Annual Shareholders Meeting Amidst Phase 3 Trials
2M ago
6K
PHVS
Pharvaris’s Deucrictibant: Expanding Market Reach in Bradykinin-Mediated Angioedemas with Promising Phase 3 Trials
PremiumRatings
Pharvaris’s Deucrictibant: Expanding Market Reach in Bradykinin-Mediated Angioedemas with Promising Phase 3 Trials
2M ago
PHVS
Pharvaris’s Strategic Advancements and Clinical Progress Justify Buy Rating
PremiumRatingsPharvaris’s Strategic Advancements and Clinical Progress Justify Buy Rating
2M ago
PHVS
Pharvaris presents data supporting ongoing clinical development of deucrictibant
Premium
The Fly
Pharvaris presents data supporting ongoing clinical development of deucrictibant
2M ago
PHVS
Pharvaris: Strong Buy Rating Backed by Clinical Progress and Financial Stability
Premium
Ratings
Pharvaris: Strong Buy Rating Backed by Clinical Progress and Financial Stability
3M ago
PHVS
Pharvaris’s Promising Pipeline Progress and Strong Financial Position Justify Buy Rating with $43 Target
PremiumRatings
Pharvaris’s Promising Pipeline Progress and Strong Financial Position Justify Buy Rating with $43 Target
3M ago
PHVS
Pharvaris price target raised to $27 from $25 at Wedbush
PremiumThe Fly
Pharvaris price target raised to $27 from $25 at Wedbush
3M ago
PHVS
Pharvaris price target lowered to $25 from $28 at Cantor Fitzgerald
PremiumThe Fly
Pharvaris price target lowered to $25 from $28 at Cantor Fitzgerald
3M ago
PHVS
Pharvaris: Strong Buy Rating Backed by Regulatory Success and Promising Clinical Progress
PremiumRatings
Pharvaris: Strong Buy Rating Backed by Regulatory Success and Promising Clinical Progress
3M ago
PHVS
Pharvaris reports Q1 EPS EUR (0.85) vs. EUR (0.52) last year
PremiumThe FlyPharvaris reports Q1 EPS EUR (0.85) vs. EUR (0.52) last year
3M ago
PHVS
Pharvaris Reports Q1 2025 Financials and Advances HAE Treatment Trials
Premium
Company Announcements
Pharvaris Reports Q1 2025 Financials and Advances HAE Treatment Trials
3M ago
6K
PHVS
Pharvaris initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
Pharvaris initiated with an Overweight at Cantor Fitzgerald
3M ago
PHVS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >